2017 CABS Investor Forum
Date: January 11, 2017 @ 8:00 am – @ 12:00 pm
Location: Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482
2017 CABS Investor Forum
About the Event:
Back by popular demand, CABS is very pleased to announce that the 2017 CABS Investor Forum will be held on January 11, 2017 (Wednesday), in conjunction with JP Morgan Healthcare Conference 2017 in San Francisco.
Chinese investments in US businesses hit a record of $15B last year, with California remaining a top destination. Chinese direct investment in the US biotech and health sector has seen a dramatic increase recently. This event will celebrate the establishment of new multi-national investment funds for life sciences and successful fundraising by our entrepreneurs.
This forum, running from 8:00am-12:00pm, will feature two panel discussions joined by US/Asia healthcare investors and entrepreneurs, focused on discussing the US-Asia cross border healthcare investment trends, transactions, opportunities and challenges.Agenda:
8:00-8:55 Registration, Breakfast & Networking
8:55-9:00 Welcome Remarks by Cheni Kwok, Ph.D., CLP, President, CABS
9:00-9:15 The State of China Biotech: An Investment Perspective by Greg Scott, Founder, ChinaBio Group
9:15-10:15 Panel 1: China Healthcare Enterprises Going Global - Strategic Moves of Large Players
Moderator: Janet Xiao, Ph.D., J.D., Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP
Confirmed speakers:
Minqi Li, Investment Director, GF Securities-Bay City Capital
Scott Liu, Ph.D., CEO & Co-Founder, Shanghai Henlius Biotech, Inc.
Leidi Zhang, Managing Director, China Life Private Equity Investment Limited
Lianshan Zhang, Ph.D., Senior Vice President and Global R&D President, Jiangsu Hengrui Medicine
Howard Liang, Ph.D., CFO and Chief Strategy Officer, BeiGene
10:15-10:30 Networking Break
10:30-11:30 Panel 2: Bridging the Gap of Healthcare Innovation between US and China -- Opportunities and Challenges for Investors and Emerging Companies
Moderator: Alexis Ji, Ph.D., M.B.A., Partner, Illumina Ventures
Confirmed speakers:
James Huang, Managing Partner, Kleiner Perkins Caufield & Byers China
Judith Li, M.B.A., Partner, Lilly Asia Venture
Andrew Thompson, President & CEO, Proteus Digital Health
Michael Chang, M.B.A., Managing Director, Vivo Capital
Wei Zhou, Ph.D., J.D., President & CEO, Centrillion Bio
11:30-12:00 Networking
Speaker Biographies (alphabetical order)
James Huang, Managing Partner, Kleiner Perkins Caufield & Byers China
James Huang, M.B.A., joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. James has made more than 15 investments in China since 2007.
Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James is Chairman of Board at Kindstar Global, JHL Biotech and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory and Omni Pharmaceuticals.
James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.
Alexis Ji, Partner, Illumina Ventures
Alexis Ji, Ph.D., M.B.A., is a partner at Illumina Ventures. She brings 12 years of experience in research and venture investment in the genomics and pharmaceutical industries. At Illumina Ventures, Alexis focuses on investing in early-stage genomics technology platforms and applications in life science tools, diagnostics, therapeutics, and digital health.
Prior to Illumina Ventures, Alexis was a principal at WuXi Apptec Corporate Venture Fund and then WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm, where she focused on investments in therapeutics and medtech companies in the U.S. Alexis was instrumental in investments in Twist Bioscience, 23andme, Juno Therapeutics, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Ideaya Therapeutics, and Lumo Bodytech. Before joining WuXi, Alexis was a venture investment consultant at ARCH Venture Partners, where she evaluated early-stage life science and physical science opportunities and was involved in the founding of Twist Bioscience and the investment in Nextcode Health, and provided operating assistance to Boreal Genomics and PixelEXX Systems. Earlier in her career, Alexis worked as a senior scientist at Merck in early drug discovery, at Roche in virology translational research and clinical trial development, and at Life Technologies in molecular diagnostics and next-generation sequencing.
Alexis earned her Ph.D. in Molecular Genetics from Washington University in St. Louis, where her thesis was on non-coding RNA discovery. Alexis holds an MBA from University of Chicago Booth School of Business, and a Bachelor in Biochemistry from Shandong University.
Judith Li, Partner, Lilly Asia Venture
Judith Li, M.B.A., is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border.
Judith holds board appointments at a variety of LAV’s portfolio companies including Nextcure, Crown Biosciences, Just Biotherapeutics, and Veritas Genetics. Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture.
Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong with her husband Ben, splitting her time between Hong Kong, Shanghai, and the Bay Area.
Minqi Li, Investment Director, GF Securities-Bay City Capital
Minqi Li, CFA, is Investment Director of Bay City Capital GF XINDE Life Sciences USD Fund, a newly established life sciences VC fund jointly managed by GF XINDE and Bay City Capital. The fund invests in the broad life sciences sector, geographically in the US, Europe and China.
Minqi holds Master’s degrees in molecular medicine from Sun Yat-Sen University and genetics and genomics from Stanford University. She also holds a Master’s degree in management from Paris-Sorbonne University, France. Minqi obtained her bachelor degree in finance from Sun Yat-Sen University and got clinical medicine training in the Medical School of Sun Yat-Sen University.
Scott Liu, CEO & Co-Founder of Henlius Biotech Inc
Dr. Scott Liu, CEO & Co-Founder of Henlius Biotech Inc., graduated from Purdue University’s Department of Biology, was a postdoctoral fellow at Stanford University, and later pursued iMBA courses at Syracuse University. He has many years of experience in management and leadership. He has previously served as vice president of UBI and Bristol-Myers Squibb, and was also the QC director of Amgen. Because of his outstanding achievement, Dr. Liu has won the Bristol-Myers Squibb Company's Technical Operation Award as well as the Focus of Attention Award. In addition, he was also awarded the National Science Council of Taiwan Distinguished Investigator in 1993. Dr. Liu Scott has 20 years of experience in biopharmaceutical development, manufacturing, drug administration and quality management , and he won the title of " 1000 Planning Expert of Shanghai " in 2013.
Greg B. Scott, Founder and Chairman, ChinaBio® Group
Greg founded ChinaBio® Group in 2007 to help western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio has helped identify over 1000 partnering, licensing and acquisition candidates, and raise over $500M in gov't and VC funding in China. ChinaBio also organizes the highly successful ChinaBio Partnering Forum which draws over 850 attendees from around the world each spring. Greg is also co-founder of two private investment groups that have funded over 50 biotechnology and medical device companies in the U.S. and China, and Executive Editor of ChinaBio® Today, the most widely read source for China life science news. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, Cleveland, Toronto and Basel, Switzerland. Greg lives and works in Shanghai but occasionally visits San Diego to enjoy the blue skies and sandy beaches.
Andrew Thompson, Co-Founder, President & CEO, Proteus Digital Health
Andrew Thompson is Co-Founder, President and CEO of Proteus Digital Health. His vision for digital medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a more sustainable model for innovation that leverages the cell phone in everyone's pocket.
He is also a Co-Founder and Board Member of Summit Schools, a leading Charter School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie “Waiting for Superman”.Thompson is active in digital humanities innovation as a Member of the Stanford University Libraries and Academic Information Resources Council and with Cambridge University. He is a Co-Founder of Parker Library Online - a leading destination for digital medieval studies.
He holds master’s degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.
Janet Xiao, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP
Janet Xiao, Ph.D., J.D., is co-chair of the global Life Sciences Group of Morrison & Foerster LLP and specializes in world-wide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Recognized for her deep understanding of the pharmaceutical and biotech industries and knowledge of IP relating to the life sciences arena (Chambers Global), Janet is highly sought after for complex patent strategic and IP due diligence work. She is instrumental on the strategy for multibillion-dollar patent portfolios for pharmaceutical clients, and works extensively with U.S. and foreign life sciences clients in conducting IP due diligence in various business settings. Dr. Xiao is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China and Chinese clients, and is frequently called upon to advise clients on IP issues and conduct IP due diligence in U.S./China cross-border transactions and operations in China. In 2014, 2015 and 2016, Dr. Xiao was listed multiple times in Chambers Global as a leading IP expert in the United States and a leading IP lawyer in China as an expert based abroad.
Michael Chang, M.B.A., Managing Director, Vivo Capital
Michael Chang joined Vivo with a background in healthcare strategy and operations in both the U.S. and China. Prior to Vivo, he worked at Johnson & Johnson, where he helped establish the strategy and commercial planning function for J&J’s China medical device business. Previously, he worked for Booz & Company and Fletcher Spaght, and also co-founded a company in the vascular access space.
Michael graduated from Harvard University with a B.A. in Economics, with a focus on health policy, and an M.B.A. from Harvard Business School. He also has research experience at Harvard Medical School and University of California Irvine in brain tumor immunology and cancer genetics.
Leidi Zhang, Managing Director, China Life Private Equity Investment Limited
Ms. Zhang is a Managing Director at the China Life Private Equity Limited. Founded in 2016, China Life Private Equity Limited, is the wholly-owned subsidiary of China Life Investment Holding Company Limited, which is the alternative investment arm of China Life Group. It currently manages the China Life Healthcare Equity Investment Fund of more than RMB 12 billion.
Ms. Zhang has over 13 years of experience in private equity investment and management consulting. Previously, Ms Zhang was an Executive Director in the Private Equity Department of China Life Investment Holding Limited. Prior to that, she worked for Roland Berger Strategy Consultants as a project manager. Ms Zhang graduated from Peking University with a Master Degree of Finance.
Wei Zhou, President & CEO, Centrillion Bio
Wei Zhou, Ph.D., J.D., is Founder, President and CEO of Centrillion. While a student at Stanford, he joined the pioneering genomic technology start-up Affymetrix (now NASDAQ: AFFX) where a generation of future industry leaders and scientists were inspired to change the world for the better through genomics. He continues to be fascinated by the profound and positive impact of genomic technologies in scientific research, health care, agriculture and other fields despite the severe limitations of current genomic technologies and is passionate about making genomic technology accurate and accessible.
Prior to founding Centrillion, Dr. Zhou was a partner at the technology law firm Wilson Sonsini Goodrich & Rosati where he advised life sciences, clean tech and digital media companies and venture capital investors. He also served as a senior advisor to the global law firm Covington and Burling. At Affymetrix, he was a vice president of intellectual property and advanced technology until 2008. He was also credited with building Affymetrix’ rapidly growing China business.
Dr. Zhou received his PhD from Virginia Tech (John Lee Pratt Fellow), his postdoctoral training from Emory University Medical School and his JD from Stanford University Law School (Associate Editor, Stanford Law Review). He is also a graduate of Harvard Business School’s General Management Program.
Lianshan Zhang, Senior Vice President and Global R&D President, Jiangsu Hengrui Medicine
Dr. Lianshan Zhang holds the position of Senior Vice President and Global R&D President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NMEs across the globe, and was rewarded 1,000 Talents Plan. Prior to Hengrui, he was a senior research executive at Marcadia Biotech. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide/protein therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.
Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. (summa cum laude) in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University.
Howard Liang, CFO and Chief Strategy Officer, BeiGene
Howard Liang is the Chief Financial Officer and Chief Strategy Officer of BeiGene. Dr. Liang has more than 20 years of combined experience on Wall Street as an analyst covering the biotechnology and pharmaceutical sectors and as a scientist in the biopharmaceutical industry. Prior to BeiGene, Dr. Liang spent 10 years at Leerink Partners, where he was a Managing Director and head of biotechnology equity research. Dr. Liang was given many recognitions by the industry, including Institutional Investor All-America Research Team, Biotechnology / Mid- & Small-Cap, 2015; Bloomberg Markets Top US Analysts in Biotechnology, 2012; Wall Street Journal “Best of the Street” in Biotechnology and Pharmaceuticals, 2010 and in Biotechnology, 2008. Dr. Liang has also held senior biotechnology analyst positions at A.G. Edwards and JMP Securities. He began his career on Wall Street at Prudential Securities, where he was an associate analyst covering major and specialty pharmaceuticals. Before joining Wall Street, Dr. Liang spent eight years at Abbott Laboratories, where he was a senior scientist and a member of one of the industry's leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including 6 in Nature, Science, and Proceedings of the National Academy of Sciences.
Dr. Liang obtained his MBA and Ph.D. in Biochemistry and Molecular Biology, both from the University of Chicago, and his B.S. in Chemistry from Peking University.
.